Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development

doi:10.16352/j.issn.1001-6325.2023.07.1143

Abstract

Abstract: The immune checkpoint CD276 protein, belonging to the B7 family molecules, could interact with important signaling pathways, such as phosphatidylinositol 3 kinase/protein kinase B(PI3K/AKT)signaling pathway, resulting to the regulation of tumor energy metabolism, inhibition of the anti-tumor activity of immune cells, promotion of tumor angiogenesis, and the assistance of tumor immune escape and metastasis. CD276 also potentially related to tumor stemness and chemotherapy resistance closely. Several antibody drugs and cell therapy methods targeting at CD276 have been proved in clinical trials. CD276 can also be used as a biomarker for tumor diagnosis and subtyping. The upstream regulatory mechanisms of CD276 include transcriptional level regulation mediated by non-coding RNA and transcription factors, and post-translational modification level regulation mediated by methylation and glycosylation.

Key words: CD276, tumor immune escape, tumor pathological mechanism, tumor immunotherapy, immune checkpoint

CLC Number:

R730.3

CHEN Zhongjie, HUANG Jiaru, HU Qing, ZHAO Zhenqin, CHEN Qiaoqiao, SUN Junyuan, JIA Jing. Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development[J]. Basic & Clinical Medicine, 2023, 43(7): 1143-1147.

References

[1] Shao L, Yu Q, Xia R,et al. B7-H3 on breast cancer cell MCF7 inhibits IFN-gamma release from tumour-infiltrating T cells[J]. Pathol Res Pract, 2021, 224:153461.doi:10.1016./j.prp.2021.153461.
[2] Wang C, Li Y, Jia L, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance[J]. Cell Stem Cell, 2021, 28:1597-1613.
[3] Miyamoto T, Murakami R, Hamanishi J, et al. B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression[J]. Cancer Immunol Res, 2022, 10:56-69.
[4] Aggarwal C, Prawira A, Antonia S, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial[J]. J Immunother Cancer, 2022,10:e004424.doi: 10.1136/jitc-2021-004424.
[5] Wang J, Chen X, Xie C, et al. MicroRNA miR-29a inhibits colon cancer progression by downregulating B7-H3 expression: potential molecular targets for colon cancer therapy[J]. Mol Biotechnol, 2021,63:849-861.
[6] Liao H, Ding M, Zhou N, et al. B7H3 promotes the epithelialmesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway[J]. Mol Med Rep, 2022, 25:79.doi: 10.3892/mmr.2022.12595.
[7] Wang S, Zhang X, Ning H, et al. B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis[J]. Breast Cancer Res Treat, 2022, 193:405-416.
[8] Qin F, Lin S, Deng K, et al. Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma[J]. World J Surg Oncol, 2021, 19:275.doi: 10.1186/s12957-021-02367-3.
[9] Wang R, Ma Y, Zhan S, et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-kappaB pathway to induce VEGFA expression[J]. Cell Death Dis, 2020, 11:55.doi: 10.1038/s41419-020-2252-3.
[10] Cheng N, Bei Y, Song Y, et al. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy[J]. Biochem Pharmacol, 2021, 183:114298. doi: 10.1016/j.bcp.2020.114298.
[11] Yue G, Tang J, Zhang L, et al. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma[J]. J Gastrointest Oncol, 2021,12:38-51.
[12] Picarda E, Galbo PM, Zong H,et al. The immune checkpoint B7-H3. The immune checkpoint B7-H3 (CD276) regulates adipocyte progeni-tor metabolism and obesity development[J]. Sci Adv, 2022, 8:eabm7012.doi: 10.1126/sciadv.abm7012.
[13] Huang Z, Li Y, Hong W, et al. Identification of a ferroptosis-associated gene signature and the related therapeutic targets in head and neck squamous carcinoma[J]. Int Immunopharmacol, 2022, 102:108431.doi: 10.1016/j.intimp.2021.108431.
[14] Shi X, Day A, Bergom HE, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer[J]. NPJ Precis Oncol, 2022, 6:80.doi: 10.1038/s41698-022-00323-2.
[15] Amori G, Sugawara E, Shigematsu Y, et al. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer[J]. Prostate Cancer Prostatic Dis, 2021, 24:767-774.
[16] Gao Q, Cui L, Huang C, et al. Gastric cancer-derived mesenchymal stem cells promote gastric cancer cell lines migration by modulating CD276 expression[J]. Exp Cell Res, 2022, 422:113414.doi: 10.1016/j.yexcr.2022.113414.
[17] Zhang Y, He L, Sadagopan A, et al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR-T cells[J]. Mol Cancer Ther, 2021,20:577-588.
[18] Bachawal S, Bean GR, Krings G, et al. Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression[J]. NPJ Breast Cancer, 2020,6:14.doi:10.1038/s41523-020-0158-y.
[19] Zhao S, Wang Y, Yang N, et al. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells[J]. J Immunother Cancer, 2022, 10:e004875.doi:10.1136.
[20] Kramer K, Pandit-Taskar N, Kushner BH, et al. Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies[J]. J Hematol Oncol, 2022, 15:165.doi: 10.1186/s13045-022-01383-4.
[21] Vitanza NA, Wilson AL, Huang W, et al. Intraventri-cular B7-H3 CAR-T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety[J]. Cancer Discov, 2023, 13:114-131.
[22] Lichtman EI, Du H, Shou P, et al. Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2021, 27:3141-3153.
[23] Grote S, Urena-Bailen G, Chan KC, et al. In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment[J]. Cells, 2021, 10:1020.doi: 10.3390/cells10051020.
[24] Urena-Bailen G, Dobrowolski JM, Hou Y, et al. Preclinical evaluation of CRISPR-Edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL[J]. Int J Mol Sci, 2022, 23:12828.doi: 10.3390/ijms232112828.